BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28170128)

  • 21. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence.
    Gan CP; Hamid S; Hor SY; Zain RB; Ismail SM; Wan Mustafa WM; Teo SH; Saunders N; Cheong SC
    Head Neck; 2012 Mar; 34(3):344-53. PubMed ID: 21438066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines.
    Heiduschka G; Lill C; Schneider S; Seemann R; Kornek G; Schmid R; Kotowski U; Thurnher D
    Strahlenther Onkol; 2014 May; 190(5):472-9. PubMed ID: 24557056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
    Abrahão AC; Giudice FS; Sperandio FF; Pinto Junior Ddos S
    J Oral Pathol Med; 2013 Nov; 42(10):793-8. PubMed ID: 23679684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The histone deacetylase inhibitor trichostatin A reduces lysosomal pH and enhances cisplatin-induced apoptosis.
    Eriksson I; Joosten M; Roberg K; Ollinger K
    Exp Cell Res; 2013 Jan; 319(1):12-20. PubMed ID: 23063877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiosensitization of head and neck cancer cells by the phytochemical agent sulforaphane.
    Kotowski U; Heiduschka G; Brunner M; Czembirek C; Eder-Czembirek C; Schmidt R; Fahim T; Thurnher D
    Strahlenther Onkol; 2011 Sep; 187(9):575-80. PubMed ID: 21858418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
    Streubel G; Schrepfer S; Kallus H; Parnitzke U; Wulff T; Hermann F; Borgmann M; Hamm S
    Sci Rep; 2021 May; 11(1):9587. PubMed ID: 33953226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to cisplatin by targeting survivin gene expression.
    Khan Z; Tiwari RP; Khan N; Prasad GB; Bisen PS
    Curr Gene Ther; 2012 Dec; 12(6):444-53. PubMed ID: 22974420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines.
    Czembirek C; Eder-Czembirek C; Erovic BM; Turhani D; Selzer E; Thurnher D
    Oncol Rep; 2005 Dec; 14(6):1523-6. PubMed ID: 16273249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.
    Zagni C; Pistarà V; Oliveira LA; Castilho RM; Romeo G; Chiacchio U; Rescifina A
    Eur J Med Chem; 2017 Dec; 141():188-196. PubMed ID: 29031066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
    Zhang Y; Jung M; Dritschilo A; Jung M
    Radiat Res; 2004 Jun; 161(6):667-74. PubMed ID: 15161353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
    Chan LP; Chou TH; Ding HY; Chen PR; Chiang FY; Kuo PL; Liang CH
    Biochim Biophys Acta; 2012 Jul; 1820(7):1081-91. PubMed ID: 22554915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
    Möckelmann N; Rieckmann T; Busch CJ; Becker B; Gleißner L; Hoffer K; Omniczynski M; Steinmeister L; Laban S; Grénman R; Petersen C; Rothkamm K; Dikomey E; Knecht R; Kriegs M
    Oncotarget; 2016 Apr; 7(17):23542-51. PubMed ID: 27015558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-cancer activity of a new dihydropyridine derivative, VdiE-2N, in head and neck squamous cell carcinoma.
    Goto RN; Sobral LM; Sousa LO; Garcia CB; Lopes NP; Marín-Prida J; Ochoa-Rodríguez E; Verdecia-Reyes Y; Pardo-Andreu GL; Curti C; Leopoldino AM
    Eur J Pharmacol; 2018 Jan; 819():198-206. PubMed ID: 29221949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells.
    Schrenk C; Bollmann LM; Haist C; Bister A; Wiek C; Wecker M; Roth D; Petzsch P; Köhrer K; Hamacher A; Hanenberg H; Fluegen G; Kassack MU
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma.
    Jeon YJ; Ko SM; Cho JH; Chae JI; Shim JH
    Int J Mol Med; 2013 Oct; 32(4):860-6. PubMed ID: 23877235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
    Ellerhoff TP; Berchtold S; Venturelli S; Burkard M; Smirnow I; Wulff T; Lauer UM
    Int J Oncol; 2016 Nov; 49(5):1931-1944. PubMed ID: 27601235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AZD5582, an IAP antagonist that leads to apoptosis in head and neck squamous cell carcinoma cell lines and is eligible for combination with irradiation.
    Kadletz L; Enzenhofer E; Kotowski U; Altorjai G; Heiduschka G
    Acta Otolaryngol; 2017 Mar; 137(3):320-325. PubMed ID: 27739348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the coffee ingredient cafestol on head and neck squamous cell carcinoma cell lines.
    Kotowski U; Heiduschka G; Seemann R; Eckl-Dorna J; Schmid R; Kranebitter V; Stanisz I; Brunner M; Lill C; Thurnher D
    Strahlenther Onkol; 2015 Jun; 191(6):511-7. PubMed ID: 25575980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival.
    Woo SH; Sandulache VC; Yang L; Skinner HD
    Methods Mol Biol; 2014; 1165():11-8. PubMed ID: 24839015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.